BACKGROUND: Dexmedetomidine has shown beneficial effects in several inflammatory models, including ischemia-reperfusion injury (IRI). This study investigated whether the continuous infusion of dexmedetomidine could improve renal IRI in rats. METHODS: Rats were subjected to either a sham operation and given pentobarbital (10 mg/kg/h; n=6) or were subjected to 45 minutes of renal ischemia and anesthetized with pentobarbital (10 mg/kg/h; n=6), dexmedetomidine (10 or 20 μg/kg/h; both n=6), or both pentobarbital (10 mg/kg/h) and dexmedetomidine (1.0 μg/kg/h; n=6) for 6 hours of reperfusion. Blood urea nitrogen and serum creatinine were measured 6 hours after reperfusion. Gene expression mediated by inflammatory systems in the kidney was measured with the real-time reverse-transcriptase polymerase chain reaction. RESULTS: Treatment with 10 or 20 μg/kg/h of dexmedetomidine reduced renal dysfunction. The increases in the messenger RNA expression of interleukin-6, intercellular adhesion molecule 1, and inducible nitric oxide synthase caused by renal IRI were suppressed. Under In rats under pentobarbital anesthesia, 1.0 μg/kg/h of dexmedetomidine also improved renal dysfunction after renal IRI. CONCLUSION: The present study demonstrates that continuous infusion of dexmedetomidine improves renal IRI. Moreover, with pentobarbital anesthesia, a dose of dexmedetomidine lower than the sedative dose also improves renal IRI.
BACKGROUND:Dexmedetomidine has shown beneficial effects in several inflammatory models, including ischemia-reperfusion injury (IRI). This study investigated whether the continuous infusion of dexmedetomidine could improve renal IRI in rats. METHODS:Rats were subjected to either a sham operation and given pentobarbital (10 mg/kg/h; n=6) or were subjected to 45 minutes of renal ischemia and anesthetized with pentobarbital (10 mg/kg/h; n=6), dexmedetomidine (10 or 20 μg/kg/h; both n=6), or both pentobarbital (10 mg/kg/h) and dexmedetomidine (1.0 μg/kg/h; n=6) for 6 hours of reperfusion. Blood ureanitrogen and serum creatinine were measured 6 hours after reperfusion. Gene expression mediated by inflammatory systems in the kidney was measured with the real-time reverse-transcriptase polymerase chain reaction. RESULTS: Treatment with 10 or 20 μg/kg/h of dexmedetomidine reduced renal dysfunction. The increases in the messenger RNA expression of interleukin-6, intercellular adhesion molecule 1, and inducible nitric oxide synthase caused by renal IRI were suppressed. Under In rats under pentobarbital anesthesia, 1.0 μg/kg/h of dexmedetomidine also improved renal dysfunction after renal IRI. CONCLUSION: The present study demonstrates that continuous infusion of dexmedetomidine improves renal IRI. Moreover, with pentobarbital anesthesia, a dose of dexmedetomidine lower than the sedative dose also improves renal IRI.
Authors: E Erkılıç; E Kesimci; F Alaybeyoğlu; I Kılınç; R Tural; A Yazgan; T Gümüş; A Sepici Dinçel; E G Dumlu; O Kanbak Journal: Drug Des Devel Ther Date: 2017-03-08 Impact factor: 4.162
Authors: Jun Chen; Richard Perez; Angelo Mario de Mattos; Cecilia Wang; Zhongmin Li; Richard L Applegate; Hong Liu Journal: Clin Transl Sci Date: 2020-06-16 Impact factor: 4.689
Authors: Özge Kuzgun; Sevda Özkardeşler; Şule Özbilgin; Mert Akan; Bekir Uğur Ergür; Gonca Kamacı; Mehmet Ensari Güneli; Nazire Ateş; Ali Rıza Şişman; Reci Meseri Dalak Journal: Turk J Anaesthesiol Reanim Date: 2018-09-06
Authors: Charles A Flanders; Alistair S Rocke; Stuart A Edwardson; J Kenneth Baillie; Timothy S Walsh Journal: Crit Care Date: 2019-12-11 Impact factor: 9.097